RUNX1T1 and diffuse large B-cell lymphoma: Noteworthy, we found that tafasitamab significantly increased VNR and ETO intracellular concentrations in DLBCL cell lines, compared to cells treated without tafasitamab, (except for the antagonist combination of tafasitamab plus ETO in SU-DHL10 cells).